Important note: Information in this article was accurate in 2003. The state of the art may have changed since the publication date.
Los Angeles Times (09.01.03) - Wednesday, September 10, 2003
Linda Marsa
When used with the antiviral drug interferon, the drug Zadaxin could help thousands of patients better fight HCV. "This medication looks promising for people who don't respond to other drugs," said Dr. Sammy Saab, liver specialist at UCLA's David Geffen School of Medicine. "It may also be used as part of a combination drug cocktail for all hepatitis C sufferers, since it seems to work by a different mechanism of action than other medications," added Saab.
Current HCV treatment - a combination of interferon and Ribarvirin - helps only half of those with active infections and less than a third who are infected with the more prevalent and more dangerous form of hepatitis C known as genotype 1.
Zadaxin is a synthetic version of thymosin alpha 1, a naturally occurring protein that stimulates the production of certain immune system cells. The drug, which has no apparent side effects, is approved for sale in 30 countries as an antiviral drug to treat hepatitis B but only in a few countries to fight hepatitis C.
However, results of a US study using Zadaxin to treat HCV were encouraging. The test involved 31 patients with high levels of genotype 1 who had not responded to standard therapy. Zadaxin, used in combination with interferon, greatly reduced levels of HCV in up to 36 percent of the patients.
The findings were particularly significant because patients who do not respond to the initial round of treatment rarely benefit from subsequent therapy. "We purposely chose the most difficult of the most-difficult-to-treat patients," said researcher Di Bisceglie. Zadaxin is in the final phase of US trials.
Around 4 million Americans are infected with HCV, and about 2.7 million of those have an active infection in which the liver is inflamed. Hepatitis C, which kills 10,000 people a year, is the leading cause for liver transplants in the United States.
030910
AD031834
Copyright © 2003 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .